Inventor

DE PLAEN ETIENNE

BE25 patents

⚠️ This page may combine multiple inventors who share the name “DE PLAEN ETIENNE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

DE PLAEN ETIENNE

LUDWIG INST CANCER RES

Isolated nonapeptides derived from MAGE genes and uses thereof

Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Isolated nucleic acid molecules which encode MAGE derived nonapeptides

Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor

Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Method for treating cancer by administering MAGE-derived peptides

Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors

Tumor rejection antigen precursors, tumor rejection antigens and uses thereof

Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals

Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

Precursor processed to at least one tumor rejection antigen presented by HLA-A2

Tumor rejection antigens

Isolated nonapeptides presented by HLA molecules, and uses thereof

Method for determining cancer by determining expression of MAGE-10

Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals

HUANG LAN-QING

Tumour rejection antigens